Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Caris, Threshold Pharmaceuticals to Develop Cancer Drug Response Assay

Caris, Threshold Pharmaceuticals to Develop Cancer Drug Response Assay

Oct 25, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Caris Life Sciences and Threshold Pharmaceuticals announced today that they have partnered to develop a tissue-based assay to predict how pancreatic cancer patients will respond to Threshold’s investigational drug evofosfamide.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
22
Featured Webinar

Trends in Variant Interpretation Workflows: Expert Insights to Advance NGS Oncology Profiling

Sponsored by
Qiagen

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

What's Popular?

In Cancer

  1. Oppenheimer Initiates Coverage of DermTech With Outperform Rating

  2. OncoLab Diagnostics Targets Cancer Recurrence Monitoring with CTC-Derived Biomarker Assay

    Premium

  3. NeoGenomics to Boost Growth of Pharma, Informatics Divisions Through CDx Agreements, Acquisitions

    Premium

  4. Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines

  5. Caris Shares Data for AI-Driven Tumor Origin Prediction, Hinting at Diagnostic, Patient Benefit

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.